Protalix BioTherapeutics (FRA:PBDA) Ending Cash Position: €23.80 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PBDA Protalix BioTherapeutics Inc FRA:PBDA
56 GF Score
Price €2.00
GF Value €1.89
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Protalix BioTherapeutics Ending Cash Position?

Protalix BioTherapeutics FRA:PBDA +2.15% 56 Ending Cash Position is €23.80 Mil as of Jun. 2026. GuruFocus rates FRA:PBDA with a GF Score™ of 56/100 and a GF Value™ of €1.89 (Fairly Valued). The stock has 4 warning signs investors should review.

Protalix BioTherapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 was €23.80 Mil.

Protalix BioTherapeutics's quarterly Ending Cash Position increased from Dec. 2025 (€12.54 Mil) to Mar. 2026 (€35.47 Mil) but then declined from Mar. 2026 (€35.47 Mil) to Jun. 2026 (€23.80 Mil).

Protalix BioTherapeutics's annual Ending Cash Position declined from Dec. 2023 (€21.67 Mil) to Dec. 2024 (€18.87 Mil) and declined from Dec. 2024 (€18.87 Mil) to Dec. 2025 (€12.54 Mil).

Protalix BioTherapeutics Ending Cash Position Related Terms

Protalix BioTherapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Protalix BioTherapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protalix BioTherapeutics Ending Cash Position Chart

Protalix BioTherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.50 16.15 21.67 18.87 12.54

Protalix BioTherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.52 11.63 12.54 35.47 23.80
FRA:PBDA
56GF Score
Protalix BioTherapeutics Inc FRA:PBDA
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protalix BioTherapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Protalix BioTherapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=16.876+-4.339
=12.54

Protalix BioTherapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=35.589+-11.788
=23.80

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €23.80 Mil mean?
Protalix BioTherapeutics (FRA:PBDA) has a Ending Cash Position of €23.80 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Protalix BioTherapeutics and its competitors.
Is Protalix BioTherapeutics' Ending Cash Position too high?
Protalix BioTherapeutics' current Ending Cash Position is €23.80 Mil. Overall, Protalix BioTherapeutics has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' Ending Cash Position compare to GLSI and DTIL?
Protalix BioTherapeutics' Ending Cash Position of €23.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Protalix BioTherapeutics and its competitors. Protalix BioTherapeutics's current Ending Cash Position is €23.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (FRA:PBDA) is currently considered Fairly Valued. The stock's GF Value™ is €1.89, compared to a current price of €2.00 — trading 5.8% above its estimated fair value. The current Ending Cash Position is €23.80 Mil. Protalix BioTherapeutics' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Protalix BioTherapeutics (FRA:PBDA), the current Ending Cash Position is €23.80 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Protalix BioTherapeutics (FRA:PBDA) Overvalued in 2026?

Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued. The current stock price of €2.00 is trading 5.8% above its estimated GF Value™ of €1.89. GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.

Key valuation signals for FRA:PBDA:

  • Ending Cash Position: €23.80 Mil
  • GF Value™: €1.89 vs. price of €2.00 (5.8% above fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the FRA:PBDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protalix BioTherapeutics Business Description

Other Exchanges PLX:USA
Address 2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
56GF Score

Get the complete analysis for FRA:PBDA

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.00
Price
€1.89
GF Value